Johnson & Johnson (US), Bristol-Myers Squibb (US), C. H. Boehringer Sohn (Germany), and Pfizer, Inc. (US) Dominate the US Anticoagulation Therapy Market for Drugs
The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from an estimated USD 18.49 Billion in 2017, at a CAGR of 8.5%. In 2016, C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), and Pfizer (US) dominated the market. Johnson & Johnson dominated the US anticoagulation therapy market for drugs in 2016. Johnson & Johnson’s leading position in the market can be attributed to its highest selling NOAC-Xarelto. The company has a strong presence across the globe and operates through 230 wholly owned subsidiaries located in more than 60 different countries in North America, Europe, the Middle East & Africa, and Asia Pacific. Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=114158575 Bristol-Myers Squibb (US) and Pfizer (US) collaboratively held the second position in the US anticoagulation therapy market for drugs. The company’s patented NOAC-Eliquis-is the fastest gr...